Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms
Journal of Clinical Oncology (JCO) Podcast · Jonathan W. Riess
June 18, 20188m 40s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This podcast discusses the important risks and potential benefits of PD-1 immune checkpoint blockade in patients with thymic epithelial neoplasms.
Read the related article "Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial" on JCO.org